News

Pharmabiz11m
Merck to initiate EXPrESSIVE phase 3 trials of MK-8527, an investigational once-monthly HIV prevention pill
Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...
Medical Dialogues1d
Merck to begin Phase 3 trials for investigational once monthly HIV prevention pill
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
PharmExec5d
Alzheimer’s Drug Discovery Foundation Provides Transposon Therapeutics with Investment to support Alzheimer’s Treatment TPN-101
TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.
Medical Dialogues5d
Merck application for two drug regimen for adults with virologically suppressed HIV 1 infection under USFDA review
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...
Managed Healthcare Executive5d
FDA Accepts NDA for Investigational HIV Regimen, Doravirine/Islatravir
If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...
MPR6d
NRTI Use Linked to Risk for Primary Open-Angle Glaucoma
Increased risk seen in adjusted analyses in association with nucleoside and nucleotide reverse transcriptase inhibitor use.